The Wall Street Journal reported on February 2 that the Biden administration has reached a $230 million agreement with Elume, an Australian diagnostic company, to produce household over-the-counter coronavirus testing products.
The U.S. Food and Drug Administration (FDA) has previously approved this test product.
So far, the FDA has approved three coronavirus tests that can be completed completely at home, but Elume’s testing is the only product that does not require a prescription.
None of these three test products have been widely on the market.
Elume is expected to produce 19 million tests per month by the end of the year, Andy Slavitt, a senior adviser to the White House coronavirus task force, said Monday.
Under the agreement, 8.5 million of these will be guaranteed to be provided to the U.S. government.